Stock Movers: Apple's Tariff Woes, CVS Favors Novo Nordisk Over Eli Lilly, Spotify's Mixed Outlook

Apple Faces Tariff Headwinds and China Slowdown

• 🍎 Apple's stock declined following its earnings report, failing to alleviate investor concerns about escalating tariff costs and a slowdown in China.
• 📈 The company anticipates $900 million in higher costs due to tariffs in the current quarter, impacting its financial outlook.
• 📉 Apple's shares fell 3.7% on Friday, lagging behind the S&P 500's performance and extending year-to-date losses.

Healthcare Competition Heats Up: Wegovy vs. Zepbound

• 💊 CVS has chosen to make Novo Nordisk's Wegovy more widely available, moving Eli Lilly's Zepbound off its preferred drug list.
• 💰 This decision could give Novo Nordisk an edge in the competitive obesity market, despite Wegovy's higher initial price point.
• ⚠️ Eli Lilly's stock dropped significantly, highlighting the pressure from this intensifying competition in the GLP-1 drug space.

Spotify's Profit Concerns and App Update Boost

• 🎧 Spotify's shares tumbled after a muted outlook for profit and subscriber growth, missing analyst expectations.
• 📊 The company forecast gross profit margins of 31.5% for the second quarter, falling short of projections.
• 🚀 Despite the concerns, a subsequent announcement that the EPO approved Spotify's US app update, allowing direct pricing access, helped lift the stock later in the week.
• ✅ Spotify remains up year-to-date, showing resilience despite economic turbulence and price increases.